Daily vamorolone treatment for Duchenne muscular dystrophy suggested efficacy at doses of 2.0 and 6.0 mg/kg/d in an exploratory 24-week open-label study.
Late chronotype and daytime sleepiness are associated with unhealthy life habits, including consumption of alcohol and caffeinated beverages and smoking high school students.
Researchers find once-daily treatment with lemborexant is associated with a noticeable reduction in subject-reported fatigue over 6 month period in patients with insomnia disorder.
Researchers discovered that bariatric surgery led to a significant decrease in BMI, waist circumference, neck circumference, and AHI compared with in the optimized clinical treatment group.
Meal consumption in the evening is greater in obese adolescents compared with overweight or normal weight subjects, with later circadian phase of peak intake and lower amplitude.
Treatment with pitolisant, a potent and highly selective H3-receptor antagonist/inverse agonist, reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Common early onset treatment-emergent adverse events associated with solriamfetol include headache, anorexia, and nausea in patients with obstructive sleep apnea and narcolepsy.
Treatment with brivaracetam may be a potentially effective adjunct therapy in patients with drug-resistant focal or generalized epilepsies with seizures that have not previously responded to or who cannot tolerate levetiracetam.
In a clinical practice guideline, updated recommendations are presented for the evaluation and management of attention-deficit/hyperactivity disorder (ADHD) in children.
